Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

NCT00891267 Phase 3 COMPLETED

The purpose of this study is to study the effect of two doses of olmesartan medoxomil and amlodipine on vascular markers in hypertensive patients with metabolic syndrome.

Details

Lead sponsor	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase	Phase 3
Status	COMPLETED
Enrolment	60
Start date	2008-10
Completion	2011-05

Conditions

• Metabolic Syndrome
• Hypertension

Interventions

• Olmesartan medoxomil tablets low dose
• Olmesartan medoxomil tablets high dose
• Amlodipine

Primary outcomes

• To investigate the anti-inflammatory effect of Olmesartan (OM) higher dose compared to Olmesartan (OM) lower dose and amlodipine (AML) on the change in levels of the inflammatory marker hs-CRP — 6 weeks for each treatment

Countries

Germany